Coherus FDA Friday, December 17, 2021 +0.70 Positive

FDA Approves YUSIMRY — Coherus BioSciences Inc

On December 17, 2021, the FDA approved Coherus BioSciences' commercial footprint by granting accelerated approval for YUSIMRY (adalimumab-aqvH), the rapidly-subcutaneous formulation of Humira. This launch is expected to provide a cost-effective alternative to Humira by mitigating the financial advantages of AbbVie’s offset agreements, thereby significantly impacting the competitive landscape for biologics in autoimmune markets.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed